Abstract
Our rapidly expanding understanding of the molecular pathogenesis of a variety of cancers is providing new molecular targets for drug development; specifically, immunomodulatory and antiangiogenic agents are poised to become essential in novel cancer therapeutics. Rationale for the development of such therapies rest in the observation that these immune and angiogenic targets (e.g. TNF-α , VEGF, IL-6, IL-2 and IFN-γ ) are at the core of cancer growth and progression, and are aberrant and deregulated in many human malignancies. Successful immunomodulation and inhibition of aberrant angiogenesis pathways are essential for malignant tumor cells. Herein we present an overview of immune modulation and angiogenesis in cancer. We will also review preclinical and clinical development, pharmacology and clinical trials of lenalidomide (Revlimid®, formerly CC-5013; Celgene Corporation), and agent that alters both pathways.
Keywords: CC-5013, immunomodulator, angiogenesis inhibitor, lenalidomide, thalidomide
Current Cancer Therapy Reviews
Title: Lenalidomide: Cancer Therapy via Antiangiogenesis and Immunomodulation
Volume: 2 Issue: 3
Author(s): Tanyifor M. Tohny, Jurgen Venitz, Alex Sparreboom and William D. Figg
Affiliation:
Keywords: CC-5013, immunomodulator, angiogenesis inhibitor, lenalidomide, thalidomide
Abstract: Our rapidly expanding understanding of the molecular pathogenesis of a variety of cancers is providing new molecular targets for drug development; specifically, immunomodulatory and antiangiogenic agents are poised to become essential in novel cancer therapeutics. Rationale for the development of such therapies rest in the observation that these immune and angiogenic targets (e.g. TNF-α , VEGF, IL-6, IL-2 and IFN-γ ) are at the core of cancer growth and progression, and are aberrant and deregulated in many human malignancies. Successful immunomodulation and inhibition of aberrant angiogenesis pathways are essential for malignant tumor cells. Herein we present an overview of immune modulation and angiogenesis in cancer. We will also review preclinical and clinical development, pharmacology and clinical trials of lenalidomide (Revlimid®, formerly CC-5013; Celgene Corporation), and agent that alters both pathways.
Export Options
About this article
Cite this article as:
Tohny M. Tanyifor, Venitz Jurgen, Sparreboom Alex and Figg D. William, Lenalidomide: Cancer Therapy via Antiangiogenesis and Immunomodulation, Current Cancer Therapy Reviews 2006; 2 (3) . https://dx.doi.org/10.2174/157339406777934690
DOI https://dx.doi.org/10.2174/157339406777934690 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Formulation and Optimization of 5-Fluorouracil Loaded Chitosan Nanoparticles Employing Central Composite Design
Drug Delivery Letters A Review on Metabolic Pathway Analysis in Biological Production
Mini-Reviews in Organic Chemistry Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials Kinase Inhibitors Targeting Anti-angiogenesis as Anti-cancer Therapies
Current Angiogenesis (Discontinued) Translational Research and Standardization in Optical Imaging
Current Molecular Imaging (Discontinued) Heparan Sulfate Proteoglycans, Tumour Progression and the Cancer Stem Cell Niche
Current Cancer Therapy Reviews Meet Our Editorial Board Member
Current Drug Delivery γ-Secretase-Regulated Signaling Typified by Notch Signaling in the Immune System
Current Stem Cell Research & Therapy Carbonic Anhydrase Inhibitors and the Management of Cancer
Current Topics in Medicinal Chemistry Functional Genomics- and Network-driven Systems Biology Approaches for Pharmacogenomics and Toxicogenomics
Current Drug Metabolism Stabilization of Eukaryotic Topoisomerase II-DNA Cleavage Complexes
Current Topics in Medicinal Chemistry Roles of E6 and E7 Human Papillomavirus Proteins in Molecular Pathogenesis of Cervical Cancer
Current Protein & Peptide Science Cholesterol-Rich Nanoemulsions (LDE) for Drug Targeting of Cholesteryl-Succinyl- 5-Fluorouracil Conjugate
Current Nanoscience Synthesis and Evaluation of Some Dibromoquinazoline-sulphonamide Hybrids and some Schiff´s Base Analogs for their Cytotoxic Activity
Anti-Cancer Agents in Medicinal Chemistry Activation of Macrophages: Establishing a Role for Polysaccharides in Drug Delivery Strategies Envisaging Antibacterial Therapy
Current Pharmaceutical Design Serous BMP8A has Clinical Significance in the Ultrasonic Diagnosis of Thyroid Cancer and Promotes Thyroid Cancer Cell Progression
Endocrine, Metabolic & Immune Disorders - Drug Targets 3D-QSAR Study on a Series of Bcl-2 Protein Inhibitors Using Comparative Molecular Field Analysis
Protein & Peptide Letters Menin, Histone H3 Methyltransferases, and Regulation of Cell Proliferation: Current Knowledge and Perspective
Current Molecular Medicine MicroRNAs and Chronic Inflammation Contribution to Gastrointestinal Integrity
Current Medicinal Chemistry Identification of VEGFR2-Binding Peptides Using High Throughput Bacterial Display Methods and Functional Assessment
Current Cancer Drug Targets